All In Biotech

Drug Trial Radar · NCT05581823

Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants

A Phase 1, Open-label, Fixed-sequence, Crossover Trial to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Induction by Carbamazepine on the Steady-state Pharmacokinetics of Tavapadon in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Apr 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Oct 19, 2022

Primary completion

Jan 27, 2023

Study completion Feb 2, 2023

Sponsor

Lead sponsor
Cerevel Therapeutics, LLCIndustry
Sponsor type
Industry
First posted
Oct 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the effect of carbamazepine, a strong CYP3A4 inducer, on the steady-state pharmacokinetics (PK) of tavapadon in healthy adult participants.

Conditions

  • Parkinson Disease

Interventions

  • TavapadonDrug

    Oral tablets

  • CarbamazepineDrug

    Extended-release oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax) of TavapadonTime frame: Pre-dose and at multiple timepoints post-dose up to Day 31
  2. Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCτ) of TavapadonTime frame: Pre-dose and at multiple timepoints post-dose up to Day 31

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Madison, Wisconsin

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.